Published in Curr Med Chem on December 01, 2004
The therapeutic implications of clinically applied modifiers of heat shock protein 70 (Hsp70) expression by tumor cells. Cell Stress Chaperones (2008) 1.04
Caenorhabditis elegans as a platform to study the mechanism of action of synthetic antitumor lipids. Cell Cycle (2014) 0.96
Phospholipase C and myosin light chain kinase inhibition define a common step in actin regulation during cytokinesis. BMC Cell Biol (2007) 0.96
Involvement of lipid rafts in the localization and dysfunction effect of the antitumor ether phospholipid edelfosine in mitochondria. Cell Death Dis (2011) 0.92
Lipid raft-mediated Akt signaling as a therapeutic target in mantle cell lymphoma. Blood Cancer J (2013) 0.91
Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeast. J Biol Chem (2013) 0.90
Lipid raft involvement in yeast cell growth and death. Front Oncol (2012) 0.90
Necroptosis is associated with low procaspase-8 and active RIPK1 and -3 in human glioma cells. Oncoscience (2014) 0.89
Combination of the anti-tumour cell ether lipid edelfosine with sterols abolishes haemolytic side effects of the drug. J Chem Biol (2008) 0.82
Glycosidated phospholipids: uncoupling of signalling pathways at the plasma membrane. Br J Pharmacol (2010) 0.81
Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines. Blood Cancer J (2014) 0.81
The SK3/K(Ca)2.3 potassium channel is a new cellular target for edelfosine. Br J Pharmacol (2011) 0.81
Exogenous ether lipids predominantly target mitochondria. PLoS One (2012) 0.81
Vitamin E prevents lipid raft modifications induced by an anti-cancer lysophospholipid and abolishes a Yap1-mediated stress response in yeast. J Biol Chem (2010) 0.79
The orally available, synthetic ether lipid edelfosine inhibits T cell proliferation and induces a type I interferon response. PLoS One (2014) 0.78
Cell membrane modulation as adjuvant in cancer therapy. Cancer Treat Rev (2016) 0.76
Endoplasmic reticulum targeting in Ewing's sarcoma by the alkylphospholipid analog edelfosine. Oncotarget (2015) 0.75
nsPEF-induced PIP2 depletion, PLC activity and actin cytoskeletal cortex remodeling are responsible for post-exposure cellular swelling and blebbing. Biochem Biophys Rep (2016) 0.75
Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res (2006) 1.94
Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. AIDS (2004) 1.37
Fas/CD95 death receptor and lipid rafts: new targets for apoptosis-directed cancer therapy. Drug Resist Updat (2006) 1.25
High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. J Virol (2005) 1.24
The dual role of thymidine phosphorylase in cancer development and chemotherapy. Med Res Rev (2009) 1.22
Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol (2006) 1.21
Combinatorial SNARE complexes modulate the secretion of cytoplasmic granules in human neutrophils. J Immunol (2006) 1.16
Development of a new family of conformationally restricted peptides as potent nucleators of beta-turns. Design, synthesis, structure, and biological evaluation of a beta-lactam peptide analogue of melanostatin. J Am Chem Soc (2003) 1.13
Cytotoxicity of an anti-cancer lysophospholipid through selective modification of lipid raft composition. J Biol Chem (2005) 1.12
Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res (2008) 1.11
Endoplasmic reticulum stress in the proapoptotic action of edelfosine in solid tumor cells. Cancer Res (2007) 1.06
Molecular determinants of topoisomerase I poisoning by lamellarins: comparison with camptothecin and structure-activity relationships. J Med Chem (2005) 1.06
Molecular pharmacology and antitumor activity of Zalypsis in several human cancer cell lines. Biochem Pharmacol (2009) 1.06
Leishmania infantum expresses a mitochondrial nuclease homologous to EndoG that migrates to the nucleus in response to an apoptotic stimulus. Mol Biochem Parasitol (2008) 1.03
In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts. Clin Cancer Res (2010) 1.00
Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: a single mode of inhibition for the three HIV enzymes? Antiviral Res (2006) 0.99
Optimization of taxane binding to microtubules: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel. Chem Biol (2008) 0.95
Antitumor activity, X-ray crystal structure, and DNA binding properties of thiocoraline A, a natural bisintercalating thiodepsipeptide. J Med Chem (2007) 0.95
Rapid human melanoma cell death induced by sanguinarine through oxidative stress. Eur J Pharmacol (2013) 0.95
DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol (2005) 0.94
HIV protease inhibition: limited recent progress and advances in understanding current pitfalls. Curr Top Med Chem (2004) 0.93
Lipid rafts, endoplasmic reticulum and mitochondria in the antitumor action of the alkylphospholipid analog edelfosine. Anticancer Agents Med Chem (2014) 0.93
Structural basis for the binding of didemnins to human elongation factor eEF1A and rationale for the potent antitumor activity of these marine natural products. J Med Chem (2004) 0.92
In silico activation of Src tyrosine kinase reveals the molecular basis for intramolecular autophosphorylation. J Mol Graph Model (2004) 0.92
XPF-dependent DNA breaks and RNA polymerase II arrest induced by antitumor DNA interstrand crosslinking-mimetic alkaloids. Chem Biol (2011) 0.91
Chemistry of lipid A: at the heart of innate immunity. Chemistry (2014) 0.91
Drug uptake, lipid rafts, and vesicle trafficking modulate resistance to an anticancer lysophosphatidylcholine analogue in yeast. J Biol Chem (2013) 0.90
The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors. Mol Pharmacol (2005) 0.90
Differential targets and subcellular localization of antitumor alkyl-lysophospholipid in leukemic versus solid tumor cells. J Biol Chem (2006) 0.90
Edelfosine is incorporated into rafts and alters their organization. J Phys Chem B (2008) 0.89
Temperature-induced melting of double-stranded DNA in the absence and presence of covalently bonded antitumour drugs: insight from molecular dynamics simulations. Nucleic Acids Res (2011) 0.89
Binding of 5'-GMP to the GluR2 AMPA receptor: insight from targeted molecular dynamics simulations. Biochemistry (2005) 0.88
Overcoming the inadequacies or limitations of experimental structures as drug targets by using computational modeling tools and molecular dynamics simulations. ChemMedChem (2007) 0.88
Lipid rafts and clusters of apoptotic signaling molecule-enriched rafts in cancer therapy. Future Oncol (2010) 0.88
VSDMIP 1.5: an automated structure- and ligand-based virtual screening platform with a PyMOL graphical user interface. J Comput Aided Mol Des (2011) 0.88
3'-[4-Aryl-(1,2,3-triazol-1-yl)]-3'-deoxythymidine analogues as potent and selective inhibitors of human mitochondrial thymidine kinase. J Med Chem (2010) 0.87
Identification of aldo-keto reductase AKR1B10 as a selective target for modification and inhibition by prostaglandin A(1): implications for antitumoral activity. Cancer Res (2011) 0.87
The molecular basis of resilience to the effect of the Lys103Asn mutation in non-nucleoside HIV-1 reverse transcriptase inhibitors studied by targeted molecular dynamics simulations. J Am Chem Soc (2005) 0.87
Adrenomedullin: a new target for the design of small molecule modulators with promising pharmacological activities. Eur J Med Chem (2005) 0.86
Further naphthylcombretastatins. An investigation on the role of the naphthalene moiety. J Med Chem (2005) 0.86
Structural aspects of binding of α-linked digalactosides to human galectin-1. Glycobiology (2011) 0.86
Assessment by molecular dynamics simulations of the structural determinants of DNA-binding specificity for transcription factor Sp1. J Mol Biol (2003) 0.86
Tubulin-based structure-affinity relationships for antimitotic Vinca alkaloids. Anticancer Agents Med Chem (2012) 0.86
Structure of micelle-bound adrenomedullin: a first step toward the analysis of its interactions with receptors and small molecules. Biopolymers (2011) 0.85
Synthesis, activity, and molecular modeling studies of novel human aldose reductase inhibitors based on a marine natural product. J Med Chem (2003) 0.85
Quantitative analysis of substrate specificity of haloalkane dehalogenase LinB from Sphingomonas paucimobilis UT26. Biochemistry (2005) 0.85
Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin. Mol Cancer Ther (2008) 0.85
Mitochondrial thymidine kinase inhibitors. Curr Top Med Chem (2005) 0.84
Role of stacking interactions in the binding sequence preferences of DNA bis-intercalators: insight from thermodynamic integration free energy simulations. Nucleic Acids Res (2005) 0.84
Antiviral agents: structural basis of action and rational design. Subcell Biochem (2013) 0.84
Synthesis and biological evaluation of new selective cytotoxic cyclolignans derived from podophyllotoxin. J Med Chem (2004) 0.84
Novel anti-inflammatory action of edelfosine lacking toxicity with protective effect in experimental colitis. J Pharmacol Exp Ther (2009) 0.84
Mitochondrial-derived ROS in edelfosine-induced apoptosis in yeasts and tumor cells. Acta Pharmacol Sin (2007) 0.83
The role of Thr139 in the human immunodeficiency virus type 1 reverse transcriptase sensitivity to (+)-calanolide A. Mol Pharmacol (2005) 0.83
Role of histidine-85 in the catalytic mechanism of thymidine phosphorylase as assessed by targeted molecular dynamics simulations and quantum mechanical calculations. Biochemistry (2004) 0.82
Recent advances in thymidine kinase 2 (TK2) inhibitors and new perspectives for potential applications. Curr Pharm Des (2012) 0.82
Involvement of mitochondrial and B-RAF/ERK signaling pathways in berberine-induced apoptosis in human melanoma cells. Anticancer Drugs (2011) 0.82
Assessing carbohydrate-carbohydrate interactions by NMR spectroscopy: the trisaccharide epitope from the marine sponge Microciona prolifera. Chembiochem (2009) 0.81
Effects of the anti-neoplastic agent ET-18-OCH3 and some analogs on the biophysical properties of model membranes. Int J Pharm (2006) 0.81
Further insight into the DNA recognition mechanism of trabectedin from the differential affinity of its demethylated analogue ecteinascidin ET729 for the triplet DNA binding site CGA. J Med Chem (2006) 0.81
Interactions of bacterial cell division protein FtsZ with C8-substituted guanine nucleotide inhibitors. A combined NMR, biochemical and molecular modeling perspective. J Am Chem Soc (2013) 0.81
TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase. Curr Top Med Chem (2004) 0.81
Rationale for the opposite stereochemistry of the major monoadducts and interstrand crosslinks formed by mitomycin C and its decarbamoylated analogue at CpG steps in DNA and the effect of cytosine modification on reactivity. Org Biomol Chem (2012) 0.81
Exploring acyclic nucleoside analogues as inhibitors of Mycobacterium tuberculosis thymidylate kinase. ChemMedChem (2008) 0.81
Antitumor alkyl ether lipid edelfosine: tissue distribution and pharmacokinetic behavior in healthy and tumor-bearing immunosuppressed mice. Clin Cancer Res (2009) 0.81
Comparison of ultra-fast 2D and 3D ligand and target descriptors for side effect prediction and network analysis in polypharmacology. Br J Pharmacol (2013) 0.81
Molecular recognition of epothilones by microtubules and tubulin dimers revealed by biochemical and NMR approaches. ACS Chem Biol (2014) 0.80
Lipid rafts, death receptors and CASMERs: new insights for cancer therapy. Future Oncol (2010) 0.80
Synthesis, modeling and evaluation of 3'-(1-aryl-1H-tetrazol-5-ylamino)-substituted 3'-deoxythymidine derivatives as potent and selective human mitochondrial thymidine kinase inhibitors. Org Biomol Chem (2010) 0.80
Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations. J Am Chem Soc (2004) 0.80
Adrenomedullin: a new and promising target for drug discovery. Expert Opin Ther Targets (2006) 0.80
Structure, physiological role, and specific inhibitors of human thymidine kinase 2 (TK2): present and future. Med Res Rev (2008) 0.80
Fluorescent phenylpolyene analogues of the ether phospholipid edelfosine for the selective labeling of cancer cells. J Med Chem (2004) 0.80
Phosphorylation modulates the alpha-helical structure and polymerization of a peptide from the third tau microtubule-binding repeat. Biochim Biophys Acta (2004) 0.80
Synthesis and biological evaluation of a new series of highly functionalized 7'-homo-anhydrovinblastine derivatives. J Med Chem (2013) 0.79
Survival and apoptotic signals in the action of microtubule-targeting antitumor drugs. IDrugs (2005) 0.79
DNA structural similarity in the 2:1 complexes of the antitumor drugs trabectedin (Yondelis) and chromomycin A3 with an oligonucleotide sequence containing two adjacent TGG binding sites on opposing strands. Mol Pharmacol (2005) 0.79
Comparative binding energy analysis of haloalkane dehalogenase substrates: modelling of enzyme-substrate complexes by molecular docking and quantum mechanical calculations. J Comput Aided Mol Des (2003) 0.79
Characterization of pyrimidine nucleoside phosphorylase of Mycoplasma hyorhinis: implications for the clinical efficacy of nucleoside analogues. Biochem J (2012) 0.79
Guanidinium receptors as enantioselective amino acid membrane carriers. J Am Chem Soc (2003) 0.78
Inhibitory effects of marine-derived DNA-binding anti-tumour tetrahydroisoquinolines on the Fanconi anaemia pathway. Br J Pharmacol (2013) 0.78
A 3.(ET743)-DNA complex that both resembles an RNA-DNA hybrid and mimicks zinc finger-induced DNA structural distortions. J Med Chem (2002) 0.78
Human mitochondrial thymidine kinase is selectively inhibited by 3'-thiourea derivatives of beta-thymidine: identification of residues crucial for both inhibition and catalytic activity. Mol Pharmacol (2009) 0.78
Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position. J Med Chem (2005) 0.78
Stepwise dissection and visualization of the catalytic mechanism of haloalkane dehalogenase LinB using molecular dynamics simulations and computer graphics. J Mol Graph Model (2007) 0.78
Solution structure and stability of tryptophan-containing nucleopeptide duplexes. Chembiochem (2003) 0.78
Rational design of a Tn antigen mimic. Chem Commun (Camb) (2011) 0.78
Serine versus threonine glycosylation with α-O-GalNAc: unexpected selectivity in their molecular recognition with lectins. Chemistry (2014) 0.78
gem-Difluorocarbadisaccharides: restoring the exo-anomeric effect. Angew Chem Int Ed Engl (2014) 0.78
5'-Trityl-substituted thymidine derivatives as a novel class of antileishmanial agents: Leishmania infantum EndoG as a potential target. ChemMedChem (2013) 0.78
Conformational selection in glycomimetics: human galectin-1 only recognizes syn-Ψ-type conformations of β-1,3-linked lactose and its C-glycosyl derivative. Chemistry (2013) 0.77
Potent "clicked" MMP2 inhibitors: synthesis, molecular modeling and biological exploration. Org Biomol Chem (2011) 0.77
Mechanistic insight into the catalytic activity of ββα-metallonucleases from computer simulations: Vibrio vulnificus periplasmic nuclease as a test case. Chembiochem (2011) 0.77